LOS ANGELES--(BUSINESS WIRE)--
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (AGIO) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
At the 2016 American Society of Hematology meeting, Agios revealed new information for its AG-348 and AG-519 molecules, used to treat pyruvate kinase deficiency. Agios stated that a case of Grade 2 thrombocytopenia, which reduces platelets in blood cells, was found in a patient receiving AG-519 and that after a dose of 300 mg, a serious adverse event of drug-related cholestatic hepatitis was noted in a bioavailability and food effect study. After this release, Agios stock dropped, causing investors harm.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161206006545/en/